Tonix Pharmaceuticals Holding Corp. (TNXP) AI Stock Analysis

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical firm dedicated to discovering, acquiring, developing, and licensing therapeutics and diagnostics for human diseases. Its pipeline spans immunology, rare diseases, infectious diseases, and central nervous system (CNS) disorders. Key drug candidates include TNX-1500 for organ transplant rejection and autoimmune disorders, TNX-2900 for Prader-Willi syndrome, and vaccines such as TNX-801 for smallpox and monkeypox. In CNS, the company is advancing TNX-102 SL in mid-Phase 3 trials for fibromyalgia management, TNX-1900 for migraine prevention, and TNX-1300 for cocaine intoxication. The company is headquartered in Chatham, New Jersey.

Tonix's revenue rose from $2.9M in FY2020 to $13.1M in FY2025, reflecting a 4-year revenue CAGR of 45.6%. In FY2025, revenue increased 29.8% from $10.1M in FY2024, and gross margin reached 34.7%. However, operating margin remained negative at -959.1% alongside net income of -$124.0M and EPS of -$14.32. Over earlier years, net income was -$115.0M in FY2022, -$116.7M in FY2023, and -$130.0M in FY2024. For the trailing twelve months ended June 30, 2026, revenue stood at $29.1M with an operating margin of -314.1% and EPS of -$13.06, while quarterly revenue growth YoY reached 577.9%.

As of June 30, 2026, Tonix held $176.2M in cash and short-term investments and $1.3M in total debt, yielding net cash of $175.0M and a debt-to-equity ratio of 0.01. Total assets were $254.1M against shareholders' equity of $222.3M, supported by a current ratio of 6.61. For FY2025, operating cash flow was -$99.8M and free cash flow was -$103.2M. Capital expenditures totaled $3.4M, while share buybacks accounted for $13.8M in FY2025.

Tonix has a market cap of $103.6M and an enterprise value of $1.0M. The stock trades at a price-to-sales multiple of 3.6x and an EV-to-EBITDA ratio of 0.9x, compared to the median of its US-listed Healthcare peers of 4.1x and 12.0x, respectively. Its price-to-book ratio is 0.8x. Over the past year, TNXP shares fell 67.9% and dropped 61.3% year-to-date, closing at $6.04 on October 16, 2026. By comparison, the S&P 500 (SPY) returned 16.8% over the past year and 83.0% over five years, while TNXP declined 100.0% over five years.

Wall Street analysts issue 3 Strong Buy ratings, with 0 Buy, 0 Hold, 0 Sell, and 0 Strong Sell ratings. The mean price target of $44.50 implies an upside of 636.8% compared to the last close of $6.04. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $55.0M and an EPS estimate of -$9.95. For the next fiscal year, 2 analysts project revenue of $110.9M and EPS of -$7.88. Over the last four quarters, the company recorded 1 EPS beat. The next earnings date is November 9, 2026.

This page is an AI-written research summary of Tonix Pharmaceuticals Holding Corp. (TNXP). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: TNXP income statement, TNXP balance sheet, TNXP key metrics, TNXP analyst forecast, TNXP chart. See the TNXP stock overview for the latest quote and news.